Product Description
The CA125 monoclonal antibodies recognize epitopes in the protein core of the CA125 antigen. These monoclonal antibodies show high specificity for ovarian cancer, and can be used for development of fast and sensitive homologous or heterologous assays. (Sourced from: https://www.fujirebio.com/en/products-solutions/ca125-antibodies)
Mechanisms of Action: MUC16 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fundación para la Investigación del Hospital Clínico de Valencia
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Heart Failure|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SURVIVE | N/A |
Recruiting |
Breast Cancer |
2035-12-01 |
|
| NU 99G8 | N/A |
Recruiting |
Uterine Cancer|Fallopian Tube Cancer|Breast Cancer|Leiomyoma|Sarcoma|Vaginal Cancer|Endometrial Cancer|Ovarian Cancer|Vulvar Cancer|Cervical Cancer|Myofibroma |
2030-12-01 |
|
| ChiCTR2400089195 | N/A |
Recruiting |
Endometrial Cancer |
2027-05-31 |
|
| ChiCTR2400079698 | N/A |
Not yet recruiting |
Breast Cancer |
2026-12-31 |